JUVENILE MYOCLONIC EPILEPSY: FOCUS ON THE USE OF TOPIRAMATE (LITERATURE REVIEW AND OWN DATA)
https://doi.org/10.17650/2073-8803-2017-12-2-8-20
Abstract
Juvenile myoclonic epilepsy (JME) is an inherited genetic syndrome within the group of idiopathic generalized epilepsies (IGE). The disease is characterized by an adolescence-onset with massive myoclonic seizures often combined with generalized convulsive seizures and absence seizures and by typical changes in the electroencephalogram appearing as short generalized polyspike-and-wave epileptiform discharges with a frequency of 3–6 Hz. Despite the high rate of remission (75–85 %) in patients receiving adequate therapy, this form of epilepsy brings more significant inconveniences for patients than many other forms of IGE. Such factors as violation of sleep hygiene, missing the doses of antiepileptic drugs (AED) or discontinuing the therapy cause recurrence of seizures in the vast majority of patients with JME, even in those with long-term remission. Due to the high recurrence rate in patients with JME, the treatment is usually lengthy; thus, the issues of its efficacy and tolerability, as well as the choice of starting therapy are particularly important in the case of JME. The impact of AED on the reproductive functions in women is a subject of major concern, since the active period of the disease and antiepileptic therapy covers the adult (and often adolescent) age.
Valproic acid was widely used for treatment of JME, but now this drug is prescribed less frequently (especially in girls and women) due to the possible negative impact on reproductive function and its teratogenic effect. So, choosing an alternative drug with high efficacy and tolerability is crucial for patients with JME. The authors present their own experience of JME treatment with topiramate. Our results suggest that topiramate is a highly effective well-tolerated drug that can be used for JME therapy without a significant impact on the reproductive functions in female patients.
About the Authors
K. Yu. Mukhin
Svt. Luka’s Institute of Child Neurology and Epilepsy
Russian Federation
6 Svetlaya Str., Puchkovo Village, Pervomayskoe Settlement, Moscow 108808
Russian Federation
6 Svetlaya Str., Puchkovo Village, Pervomayskoe Settlement, Moscow 108808
O. A. Pylaeva
Svt. Luka’s Institute of Child Neurology and Epilepsy
Russian Federation
6 Svetlaya Str., Puchkovo Village, Pervomayskoe Settlement, Moscow 108808
Russian Federation
6 Svetlaya Str., Puchkovo Village, Pervomayskoe Settlement, Moscow 108808
References
1. КарловВ.А., Фрейдкова Н.В. Юношеская миоклоническая эпилепсия. Вкн.: Эпилепсия у детей и взрослых женщин имужчин. М.: Медицина, 2010. С. 244–248. [Karlov V.A., Freidikova N.V. Juvenile myoclonic epilepsy. In: Epilepsy in children and adult women and men. Moscow: Meditsina, 2010. Pp. 244–248. (In Russ.)].
2. Миронов М.Б., Мухин К.Ю., Петрухин А.С., Холин А.А. Контроль эффективности лечения пациентов с юношескими формами идиопатической генерализованной эпилепсии и состояние «псевдоремиссии». Журнал неврологии и психиатрии им. С.С. Корсакова 2005;105(8):24–8. [Mironov M.B., Mukhin K.Yu., Petrukhin A.S., Kholin A.A. Control of the efficacy of the treatment of juvenile idiopathic generalized epilepsy and «pseudoremission». Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2005;105(8):24–8. (In Russ.)].
3. Мухин К.Ю. Юношеская миоклоническая эпилепсия (синдром Янца). В кн.: Идиопатические формы эпилепсии: систематика, диагностика, терапия. М.: Арт-Бизнес-Центр, 2000. С. 120–135. [Mukhin K.Yu. Juvenile myoclonic epilepsy (Janz syndrome). In: Idiopathic epilepsy: systematics, diagnosis, treatment. Moscow: Art-Business-Center, 2000. Pp. 120–135. (In Russ.)].
4. Мухин К.Ю., Миронов М.Б., Глухова Л.Ю. Клинико-электроэнцефалографические изменения при юношеской миоклонической эпилепсии (лекция). Русский журнал детской неврологии 2014;9(3):30–5. [Mukhin K. Yu., Mironov M.B., Glukhova L.Yu. Clinical and electroencephalographic changes in patients with juvenile myoclonic epilepsy (a lecture). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2014;9(3): 30–5. (In Russ.)].
5. Мухин К.Ю., Пылаева О.А. Безопасность и переносимость антиэпилептических препаратов у женщин с эпилепсией (данные Института детской неврологии и эпилепсии им. Святителя Луки). Русский журнал детской неврологии 2015;10(1):16–23. [Mukhin K.Yu., Pylaeva O.A. Safety and tolerability of antiepileptic drugs in women with epilepsy (the data of Svt. Luka’s Institute of Child Neurology and Epilepsy). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2015;10(1):16–23. (In Russ.)].
6. Мухин К.Ю., Фрейдкова Н.В., Глухова Л.Ю. и др. Юношеская миоклоническая эпилепсия: фокус на эффективность терапии и частоту рецидивов по данным длительного катамнеза. Русский журнал детской неврологии 2015;10(4):7–16. [Mukhin K.Yu., Freidikova N.V., Glukhova L.Yu. et al. Juvenile myoclonic epilepsy: a focus on the efficacy of therapy and the rate of relapses according to long-term follow-up data. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2015;10(4): 7–16. (In Russ.)].
7. Пылаева О.А., Мухин К.Ю., Петрухин А.С. Побочные эффекты антиэпилептической терапии. М.: Гранат, 2016. 236 с. [Pylaeva O.A., Mukhin K.Yu., Petrukhin A.S. Side effects of antiepileptic drugs. Moscow: Granat, 2016. 236 p. (In Russ.)].
8. Холин А.А., Федонюк И. Д., Колпакчи Л.М. и др. Аггравация эпилепсии при терапии леветирацетамом: наблюдение 28 клинических случаев, факторы риска и профилактика. Русский журнал детской неврологии 2013;8(4)–2014;9(1):5–22. [Kholin A.A., Fedonyuk I. D., Kolpakchi L.M. et al. Aggravation of epilepsy during therapy with levetiracetam: clinical observation of 28 cases, risk factors and prevention. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2013;8(4)–2014;9(1):5–22. (In Russ.)].
9. Auvin S., Chhun S., Berquin P. et al. Aggravation of absence seizure related to levetiracetam. Eur J Paediatr Neurol 2011;15(6):508–11. DOI: 10.1016/j.ejpn.2011.05.007.
10. Baykan B., Altindag E.A., Bebek N. et al. Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy. Neurology 2000;70(22):2123–9. DOI: 10.1212/01.wnl.0000313148.34629.1d.
11. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 2003;4(11):2079–88. DOI: 10.1517/14656566.4.11.2079.
12. Biraben A., Allain H., Scarabin J.M. et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55(11):1758. PMID: 11113246.
13. Birnbaum D., Koubeissi M. Unmasking of myoclonus by lacosamide in generalized epilepsy. Epilepsy Behav Case Rep 2016;7:28–30. DOI: 10.1016/j.ebcr.2016.09.006.
14. Camfield C.S., Camfield P.R. Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study. Neurology 2009;73(13):1041–5. DOI: 10.1212/WNL.0b013e3181b9c86f.
15. Chowdhury A., Brodie M.J. Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate. Epilepsy Res 2016;119(1):62–6. DOI: 10.1016/j.eplepsyres.2015.11.012.
16. Crespel A., Gelisse P., Reed R.C. et al. Management of juvenile myoclonic epilepsy. Epilepsy Behav 2013;28(1):S81–6. DOI: 10.1016/j.yebeh.2013.01.001.
17. Crespel A., Genton P., Berramdane M. et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65(5):762–4. DOI: 10.1212/01.wnl.0000174517.21383.36.
18. Crespel A., Velizarova R., Genton P. et al. Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate. Therapie 2009;64(5):321–3. DOI: 10.2515/therapie/2009033.
19. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42(6):796–803. PMID: 11422340.
20. Epilepsies: diagnosis and management: clinical guideline. URL: https://www.nice.org.uk/guidance (last access date: 10.05.2017).
21. Faught E. Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr Dis Treat 2007;3(6):811–21. PMID: 19300616.
22. Gelisse P., Genton P., Kuate C. et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004;45(10):1282–6. DOI: 10.1111/j.0013-9580.2004.19704.x.
23. Genton P., Gelisse P., Thomas P. Juvenile myoclonic epilepsy today: current definition and limits. In: Juvenile myoclonic epilepsy: the Janz syndrome. Petersfild and Philadelphia: WMP, 2000. Pp. 11–32.
24. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22(2): 75–80. PMID: 10722956.
25. Gesche J., Khanevski M., Solberg C., Beier C.P. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies. Epilepsia 2017;58(4):e64–e69. DOI: 10.1111/epi.13702.
26. Glauser T., Ben-Menachem E., Bourgeois B. et al. The ILAE Subcommission on AED Guidelines Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63. DOI: 10.1111/epi.12074.
27. Gomez-Ibañez A., McLachlan R.S., Mirsattari S.M. et al. Prognostic factors in patients with refractory idiopathic generalized epilepsy. Epilepsy Res 2017;130:69–73. DOI: 10.1016/j.eplepsyres.2017.01.011.
28. Grunewald R.A. Juvenile myoclonic epilepsy. In: Atlas of Epilepsies. Ed. by C.P. Panayiotopoulos. London: Springer, 2010. Pp. 1033–1040.
29. Hantus S. Idiopathic generalized epilepsy syndromes of childhood and adolescence. In: Wyllie’s treatment of epilepsy. Principles and practice. 6th edn. Ed. by E. Wyllie. Philadelphia: Wolters Kluwer, 2015. Pp. 248–258.
30. Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985;72(5):339–59. PMID: 3936330.
31. Janz D. Juvenile myoclonic epilepsy. In: Comprehensive epileptology. Eds. by M. Dam, L. Gram. New York: Raven Press, 1991. Pp. 171–185.
32. Janz D., Christian W. Impulsiv – petit mal. J Neurol 1957;176:346–86.
33. Japaridze G., Kasradze S., Lomidze G. et al. Focal EEG features and therapeutic response in patients with juvenile absence and myoclonic epilepsy. Clin Neurophysiol 2016;127(2):1182–7. DOI: 10.1016/j.clinph.2015.11.048.
34. Johannesen K., Marini C., Pfeffer S. et al. Phenotypic spectrum of GABRA1: from generalized epilepsies to severe epileptic encephalopathies. Neurol 2016;87(11):1140–51. DOI: 10.1212/WNL.0000000000003087.
35. Kwan P., Sills G.J., Brodie M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90(1):21–34. PMID: 11448723.
36. Levisohn P.M., Holland K.D. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav 2007;10(4):547–52. DOI: 10.1016/j.yebeh.2007.03.003.
37. Liu J., Wang L.N., Wang Y.P. Topiramate monotherapy for juvenile myoclonic epilepsy. Cochrane Database Syst Rev 2015;(12):CD010008. DOI: 10.1002/14651858.CD010008.pub2.
38. Loddenkemper T., Berg A.T. Terminology for seizures and epilepsies. In: Wyllie’s treatment of epilepsy. Principles and practice. 6th edn. Ed. by E. Wyllie. Philadelphia: Wolters Kluwer, 2015. Pp. 144–166.
39. Martinez-Juares I.E., Alonso M.E., Medina M.T. et al. Juvenile myoclonic epilepsy subsyndromes: family studies and longterm follow-up. Brain 2006;129(5):1269–80. DOI: 10.1093/brain/awl048.
40. Panayiotopoulos C.P. A clinical guide to epileptic syndromes and their treatment. New York: Springer, 2010. Pp. 174–179.
41. Panayiotopoulos C.P. Idiopathic generalized epilepsies. New York: Springer, 2012. Pp. 41–44.
42. Panayiotopoulos C.P., Obeid T., Tahan A.R. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994;35(2):285–96. PMID: 8156946.
43. Panayiotopoulos C.P. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001;3(5):379–403. PMID: 11393330.
44. Park K.M., Kim S.H., Nho S.K. et al. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. J Clin Neurosci 2013;20(8):1079–82. DOI: 10.1016/j.jocn.2012.10.020.
45. Perucca E. The spectrum of the new antiepileptic drugs. Acta Neurol Belg 1999;99(4):231–8. PMID: 10674140.
46. Privitera M.D., Brodie M.J., Mattson R.H. et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107(3):165–75. PMID: 12614309.
47. Shorvon S. We live in the age of the clinical guideline. Epilepsia 2 06;47(7):1091–3. DOI: 10.1111/j.1528-1167.2006.00584.x.
48. So G.M., Thiele E.A., Sanger T. et al. Electroencephalogram and clinical focalities in juvenile myoclonic epilepsy. J. Child Neurol 1998;13(11):541–5. DOI: 10.1177/088307389801301103.
49. Thomas P., Genton P., Gelisse P. et al. Juvenile myoclonic epilepsy. In: Epileptic syndromes in infancy, childhood and adolescence. 5th edn. Paris: John Libbey Eurotext, 2012. Pp. 305–328.
50. Wolf P. Juvenile myoclonic epilepsy. In: Epileptic syndromes in infancy, childhood and adolescence. Paris: John Libbey Eurotext, 1992. Pp. 316–327.
51. Yacubian E.M. Juvenile myoclonic epilepsy: challenges on its 60th anniversary. Seizure 2017;44:48–52. DOI: 10.1016/j.seizure.2016.09.005.
Review
For citations:
Mukhin K.Yu., Pylaeva O.A. JUVENILE MYOCLONIC EPILEPSY: FOCUS ON THE USE OF TOPIRAMATE (LITERATURE REVIEW AND OWN DATA). Russian Journal of Child Neurology. 2017;12(2):8-20. (In Russ.) https://doi.org/10.17650/2073-8803-2017-12-2-8-20
Views:
2121
Email this article 